R Ferreiro-Iglesias
A5050705694- Inflammatory Bowel Disease
- Microscopic Colitis
- Helicobacter pylori-related gastroenterology studies
- Autoimmune and Inflammatory Disorders
- Eosinophilic Esophagitis
- Diagnosis and treatment of tuberculosis
- Immunodeficiency and Autoimmune Disorders
- SARS-CoV-2 and COVID-19 Research
- Biosimilars and Bioanalytical Methods
- Celiac Disease Research and Management
- Radioactivity and Radon Measurements
- Mycobacterium research and diagnosis
- Pregnancy and Medication Impact
- Radiation Dose and Imaging
- Gastrointestinal motility and disorders
- Health, psychology, and well-being
- Diverticular Disease and Complications
- Vaccine Coverage and Hesitancy
- Autoimmune Bullous Skin Diseases
- IL-33, ST2, and ILC Pathways
- Clostridium difficile and Clostridium perfringens research
- Vitamin D Research Studies
- Pharmacological Effects of Natural Compounds
- Autoimmune and Inflammatory Disorders Research
- Gastrointestinal Tumor Research and Treatment
Complejo Hospitalario Universitario de Santiago
2015-2025
Instituto de Investigación Sanitaria de Santiago
2016-2025
Universidade de Santiago de Compostela
2011-2025
Complexo Hospitalario Universitario A Coruña
2021-2022
Universidad Autónoma de Madrid
2019
Hospital Universitario de La Princesa
2019
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas
2019
AbbVie (United States)
2017
Universidad de Santiago de Chile
2015
Mucosal healing in ulcerative colitis (UC) has become a common endpoint most clinical trials and relevant therapeutic goal practice. Despite important differences between endoscopic Mayo scores 0 1, both are considered as mucosal trials. The aim of the present study was to evaluate risk relapse UC patients according degree (endoscopic 1). A prospective longitudinal cohort designed. All who presented with at colonoscopy were consecutively included. defined an score or 1. Clinical need for...
The aims of this study were to determine the prevalence fatigue in patients with inflammatory bowel disease [IBD], identify factors associated and its severity, assess impact on quality life [QoL], evaluate relationship between sleep disorders.This was a prospective multicentre conducted at 22 Spanish centres. Consecutive followed IBD Units included. Fatigue evaluated Severity Scale [FSS] Impact [FIS]. Quality assessed using Questionnaire-Short Form [IBDQ-9] Pittsburgh Sleep Index [PSQI],...
(1) Aims: To assess the incidence of inflammatory bowel disease (IBD) in Spain, to describe main epidemiological and clinical characteristics at diagnosis evolution disease, explore use drug treatments. (2) Methods: Prospective, population-based nationwide registry. Adult patients diagnosed with IBD-Crohn's (CD), ulcerative colitis (UC) or IBD unclassified (IBD-U)-during 2017 Spain were included followed-up for 1 year. (3) Results: We identified 3611 incident cases during 108 hospitals...
Summary Background There are limited data of ustekinumab administered according to the doses recommended in UNITI studies. Aim To assess real‐world, short‐term effectiveness refractory Crohn's disease (CD) Methods Multicentre study CD patients starting after June 2017 at recommend dose (260, 390 or 520 mg based on weight ~6 mg/kg IV week 0 and 90 subcutaneously 8). Values for Harvey‐Bradshaw Index (HBI), C‐reactive protein (CRP) faecal calprotectin (FC) were recorded baseline weeks 8 14....
Summary Background Data on the long‐term administration of ustekinumab in recommended doses are limited. Aim To assess real‐world, effectiveness refractory Crohn's disease (CD). Methods Multi‐centre study CD patients starting at dose, followed for 1 year. Values Harvey‐Bradshaw Index (HBI), endoscopic activity, C‐reactive protein (CRP), and faecal calprotectin (FC) were recorded baseline weeks 26 52. Demographic clinical data, previous treatments, adverse events (AEs) hospitalisations...
Background: Data on ustekinumab and vedolizumab in the elderly inflammatory bowel disease (IBD) population are limited. The aim of current study was to assess safety effectiveness both an real-life population. Methods: A multicentric retrospective performed IBD patients who started or between 2010 2020. Clinical endoscopic remission rates (serious) adverse events (AE) were assessed. Results: total 911 included, with 171 (19%) aged above 60 (111 VDZ, UST). Elderly treated had increased risk...
Predicting relapse in Inflammatory Bowel Disease (IBD) could allow for early changes of treatment. Close monitoring fecal calprotectin (FC) be useful to predict IBD. Aim the study was evaluate predictive value a rapid FC test flares patients with IBD under maintenance therapy Infliximab.A prospective observational cohort designed. clinical remission Infliximab were included. measured using on stool sample obtained within 24 hours before infusion. Clinical examination performed 2 months after...
Abstract Background and Aims No consensus exists on optimal strategy to prevent postoperative recurrence [POR] after ileocaecal resection [ICR] for Crohn’s disease [CD]. We compared early medical prophylaxis versus expectant management with treatment driven by findings at elective endoscopy 6–12 months ICR. Methods A retrospective, multicentric, observational study was performed. CD patients undergoing first ICR were assigned Cohort 1 if a biologic or immunomodulator [re]started...
The management of inflammatory bowel disease (IBD) is currently based on the objective evaluation intestinal lesions. It would therefore be interesting to have access simple and non-invasive tools monitor IBD activity identify presence Faecal calprotectin (FC) main cytosolic protein neutrophils, it resistant bacterial degradation stable at room temperature for several days, characteristics that make suitable use in clinical practice. can used differentiate between functional processes,...
Background and Goal: Predicting relapse in inflammatory bowel disease (IBD) patients could allow early changes therapy. We aimed at evaluating the accuracy of consecutive fecal calprotectin (FC) measurements to predict flares IBD under maintenance treatment with anti-tumor necrosis factor (TNF) drugs. Study: A prospective longitudinal cohort study 16-month follow-up period was designed. clinical remission for least 6 months anti-TNF therapy were included. FC quantified 4-month intervals 1...
Background There is limited evidence on the effectiveness of biological therapy in stricturing complications patients with Crohn’s disease. Aim The study aims to determine anti‐tumor necrosis factor (TNF) agents disease complicated symptomatic strictures. Methods In this multicentric and retrospective study, we included adult receiving their first anti‐TNF therapy, no previous history biological, endoscopic or surgical therapy. agent was defined as a composite outcome combining steroid‐free...
Extra-intestinal manifestations are frequently reported in inflammatory bowel diseases. However, data comparing the effect of vedolizumab and ustekinumab on articular extra-intestinal limited. The aim here was to evaluate differences new-onset evolution pre-existing joint during both treatments.An international multicentre retrospective study performed disease patients who started or between May 2010 December 2020. were assessed at baseline evaluated throughout 2-year follow-up. Arthropathy...
The Montreal classification has been widely used in Crohn's disease since 2005 to categorize patients by the age of onset (A), location (L), behavior (B), and upper gastrointestinal tract perianal involvement. With evolving management paradigms disease, we aimed assess performance gastroenterologists applying classification. An online survey was conducted among participants at an international educational conference on inflammatory bowel diseases. Participants classified 20 theoretical cases...
Abstract Background Factors influencing the exposure to targeted therapies (biologics/JAKi), intestinal resections and hospitalisations in newly diagnosed IBD patients have been scarcely studied. Aim: To identify predictive factors of biologics/JAKi, surgeries, within first five years patients. Methods Prospective, population-based nationwide registry. Adult with [Crohn’s disease (CD), ulcerative colitis (UC) or unclassified (IBD-U)] during 2017 17 Spanish regions were included. Patients who...
Abstract Background Inflammatory bowel disease (IBD) patients with Clostridiodes difficile Infection (CDI) are at increased risk of exacerbations, therapy escalation, colectomy, and mortality. Data on fidaxomicin use in IBD CDI very limited. We aimed to assess the effectiveness safety for its impact outcomes a large retrospective multicenter cohort study. Methods Adult ulcerative colitis (UC) or Crohn’s (CD) episode (positive toxin enzyme immunoassay polymerase chain reaction toxigenic C....
Abstract Background Chronic refractory pouchitis (RP) is a complication of ileal pouch-anal anastomosis (IPAA). Vedolizumab (VDZ) has been used in RP management, but real-world data on its effectiveness are limited. Additionally, information switching from intravenous (IV) to subcutaneous (SC) VDZ this context scarce. Aims To evaluate the efficacy and safety treatment clinical setting, assess outcomes following transition IV SC VDZ, compare persistence between administration. Methods A...
Abstract Background Phase III trials have demonstrated the efficacy of risankizumab (RZB), this being first humanized monoclonal IgG1 antibody which targets interleukin 23 p19 subunit, in Crohn’s disease (CD). However, real-world data with drug is limited. The aim our study was to assess effectiveness RZB patients CD. Methods Adult CD that had received treatment ENEIDA registry —a large prospectively maintained Spanish database promoted by Working Group and Colitis (GETECCU)— were included....
Abstract Background The influence of Vitamin D (vitD) has been investigated in inflammatory bowel disease (IBD) patients to see how might affect activity. VitD is expected be lower winter and higher summer due sun exposure. effect IBD thought similar that healthy subjects. aim the study was evaluate fluctuation vitD undergoing different treatments during two consecutive seasons. Methods (both ulcerative colitis (UC) Crohn’s (CD)) were recruited from units Northern Spain followed-up for at...
Abstract Background and aims Inflammatory bowel disease (IBD) patients with Clostridioides difficile infection (CDI) are at increased risk of adverse outcomes. Data on fidaxomicin use in IBD remains scarce. We assessed the effectiveness safety for CDI its impact outcomes a large international cohort. Methods Adult ulcerative colitis (UC) or Crohn’s (CD) treated documented were retrospectively included. The primary outcome was recurrence rate within 8 weeks (C. toxin detection CDI-targeted...
Abstract Introduction Data about the efficacy of topical therapy with tacrolimus in patients ulcerative colitis (UC) is scarce. Therefore, this study aimed to evaluate tacrolimus's effectiveness and adverse events a real-world setting. Methods A multicenter retrospective was conducted at 27 hospitals across Spain. Adult UC who had received suppositories, enemas or ointment due persistent clinical endoscopic activity despite mesalamine and/or steroids from January 2009 2023 were included. The...